To prove the importance of the JAK pathway, someone needed to discover a compound to test the hypothesis that inhibiting the JAK enzyme was of value in treating disease.
The stock dropped after Cephalon announced that a new study had shown that its main drug, a compound called modafinil sold under the brand name Provigil, was not effective in treating Attention Deficit Hyperactivity Disorder (ADHD).